Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hugo

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Palliative Medicine|November 26, 2025
Decision-making regarding anticoagulant therapy in the last phase of life: In-depth interview study with healthcare professionals (the OPTIMA trial)Marte A M van Hylckama Vlieg, Karlijn J I de Beukelaar, Romy H L Spreeuw, et al.
The Lancet. Infectious Diseases|June 23, 2024
Profiling the SARS-CoV-2-specific T-cell responseDaryl Geers, Lennert Gommers, Ngoc H Tan, et al.
Npj Viruses|March 20, 2026
SARS-CoV-2 crossreactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemicCristina Gonzalez-Lopez, Muriel Aguilar-Bretones, Julian Reinders, et al.
The Journal of Infection|August 10, 2024
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariantsHolly A Fryer, Daryl Geers, Lennert Gommers, et al.
Frontiers in Immunology|October 25, 2021
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial ProtocolRoos S G Sablerolles, Abraham Goorhuis, Corine H GeurtsvanKessel, et al.
AIDS (London, England)|May 24, 2024
Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the NetherlandsMarlou J Jongkees, Ngoc H Tan, Daryl Geers, et al.
The New England Journal of Medicine|January 19, 2022
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S PrimingRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2022
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare WorkersRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Science Immunology|February 3, 2022
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipientsCorine H GeurtsvanKessel, Daryl Geers, Katharina S Schmitz, et al.
Iscience|December 12, 2022
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccinationDaryl Geers, Roos S G Sablerolles, Debbie van Baarle, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Palliative Medicine|November 26, 2025
Decision-making regarding anticoagulant therapy in the last phase of life: In-depth interview study with healthcare professionals (the OPTIMA trial)Marte A M van Hylckama Vlieg, Karlijn J I de Beukelaar, Romy H L Spreeuw, et al.
The Lancet. Infectious Diseases|June 23, 2024
Profiling the SARS-CoV-2-specific T-cell responseDaryl Geers, Lennert Gommers, Ngoc H Tan, et al.
Npj Viruses|March 20, 2026
SARS-CoV-2 crossreactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemicCristina Gonzalez-Lopez, Muriel Aguilar-Bretones, Julian Reinders, et al.
The Journal of Infection|August 10, 2024
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariantsHolly A Fryer, Daryl Geers, Lennert Gommers, et al.
Frontiers in Immunology|October 25, 2021
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial ProtocolRoos S G Sablerolles, Abraham Goorhuis, Corine H GeurtsvanKessel, et al.
AIDS (London, England)|May 24, 2024
Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the NetherlandsMarlou J Jongkees, Ngoc H Tan, Daryl Geers, et al.
The New England Journal of Medicine|January 19, 2022
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S PrimingRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2022
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare WorkersRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Science Immunology|February 3, 2022
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipientsCorine H GeurtsvanKessel, Daryl Geers, Katharina S Schmitz, et al.
Iscience|December 12, 2022
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccinationDaryl Geers, Roos S G Sablerolles, Debbie van Baarle, et al.
Pageof 11